Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 10/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.35 |
| ▸ | ALPL | P05186 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25295891 | 1.00 | XIAP (0.41) | XIAPBIRC2MEN1KMT2ARORC | |
| SCHEMBL32689526 | 0.91 | XIAP (0.41) | XIAPBIRC2MEN1KMT2ARORC | |
| SCHEMBL25291182 | 0.89 | NPC1 (0.45) | XIAPBIRC2MEN1KMT2ARORC | |
| SCHEMBL25298989 | 0.87 | XIAP (0.38) | XIAPBIRC2RORCKCNH2LMNA | |
| SCHEMBL25258797 | 0.87 | XIAP (0.38) | XIAPBIRC2RORCKCNH2LMNA | |
| SCHEMBL25249737 | 0.86 | XIAP (0.37) | XIAPBIRC2RORCKCNH2GRM2 | |
| SCHEMBL25295044 | 0.86 | XIAP (0.37) | XIAPBIRC2RORCKCNH2GRM2 | |
| SCHEMBL25298801 | 0.86 | XIAP (0.36) | XIAPBIRC2RORCKCNH2GRM2 | |
| SCHEMBL25248450 | 0.86 | XIAP (0.36) | XIAPBIRC2RORCKCNH2GRM2 | |
| SCHEMBL25298475 | 0.86 | XIAP (0.38) | XIAPBIRC2MEN1KMT2ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BEONE MEDICINES I GMBH (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BIRC2, BIRC3, BIRC5 | XIAP 7/4885BIRC2 1/4885MEN1 3715/4885 |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | XIAP 10/4885BIRC2 1/4885MEN1 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.